Roundtable & Audience Discussion: Operationalizing Discovery–Development Integration by Building a Shared Biophysical Framework for Better Molecule Decisions

Discussion Objectives:

• Examine how discovery, biophysics, and development groups can better align on data expectations, assay design, and molecule risk profiles
• Explore what “good” looks like for a unified biophysical strategy that flows through hit-to-lead, lead optimization, candidate nomination, and IND-enabling stage
• Identify practical quick wins, e.g., earlier aggregation screens, shared risk registers, unified CQAs, or establishing translational biophysics checkpoints, to reduce rework and late-stage surprises

Outcome:

Participants leave with a clearer understanding of how to operationalize an integrated discovery-to-development continuum and actionable ideas for improving their own internal workflows, governance models, and biophysical data strategies.

Speakers:

Ivan Budyak

Senior Director, Analytical Development Biophysical Characterization

Eli Lilly and Company

Kan Zhu

Director, Head of Analytical Biochemistry

CSL Seqirus